Follicle-stimulating hormone is associated with low bone mass in postmenopausal women.
Lindsey J MattickJennifer W BeaKathy M HoveyJean Wactawski-WendeJane A CauleyCarolyn J CrandallLili TianHeather M Ochs-BalcomPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)
FSH is associated with higher odds of having low bone mass/osteoporosis even after accounting for HT use. FSH is a mediator of the relationship between estradiol and BMD in healthy postmenopausal women. Larger, prospective studies of FSH concentrations and bone health are needed.